Mutation analysis of RAP1 gene in papillary thyroid carcinomas

Endocrine Journal

Volumn 56, Issue 1, 2009, Pages 161-164

  Matsuse, Michiko ^a   Mitsutake, Norisato ^a   Rogounovitch, Tatiana ^a   Saenko, Vladimir ^a   Nakazawa, Yuka ^a   Antsev, Pavel Rumy ^b   Lushnikov, Eugeny ^b   Suzuki, Keiji ^a   Yamashita, Shunichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b MEDICAL RADIOLOGICAL RESEARCH CENTER   (Russian Federation)

Author keywords

Mutation; Papillary thyroid cancer; RAP1

Indexed keywords

RAP1 PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MUTATIONAL ANALYSIS; ONCOGENE; RAP1A GENE; RAP1B GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RUSSIAN FEDERATION; THYROID PAPILLARY CARCINOMA;

ADULT; CARCINOMA, PAPILLARY; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEIN ISOFORMS; RAP1 GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 62549084761     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-244     Document Type: Article

References (13)

1. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS- BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457.
2. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-4580.
3. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A (2004) Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23: 7436-7440.
4. Kitayama H, Sugimoto Y, Matsuzaki T, Ikawa Y, Nöda M (1989) A ras-related gene with transformation suppressor activity. Cell 56: 77-84.
5. Stork PJ (2003) Does Rapl deserve a bad Rap? Trends Biochem Sci 28: 267-275.
6. Vossler MR, Yao H, York RD, Pan MG, Rim CS, Stork PJ (1997) cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rapl-dependent pathway. Cell 89: 73-82.
7. Stork PJ, Schmitt JM (2002) Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12: 258-266.
8. Iacovelli L, Capobianco L, Salvatore L, Sallese M, D'Ancona GM, De Blasi A (2001) Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A- independent mechanism. Mol Pharmacol 60: 924-933.
9. Ribeiro-Neto F, Leon A, Urbani-Brocard J, Lou L, Nyska A, Altschuler DL (2004) cAMP-dependent oncogenic action of Rap lb in the thyroid gland. J Biol Chem 279: 46868-46875.
10. Tsygankova OM, Prendergast GV, Puttaswamy K, Wang Y, Feldman MD, Wang H, Brose MS, Meinkoth JL (2007) Downregulation of Rapl GAP contributes to Ras transformation. Mol Cell Biol 27: 6647-6658.
11. Vanvooren V, Allgeier A, Nguyen M, Massart C, Parma J, Dumont JE, Van Sande J (2001) Mutation analysis of the Epac-Rap1 signaling pathway in cold thyroid follicular adenomas. Eur J Endocrinol 144: 605-610.
12. Zemojtel T, Penzkofer T, Duchniewicz M, Zwartkruis FJ (2006) HRap1B-retro: a novel human processed rap1B gene blurs the picture? Leukemia 20: 145-146; author reply 146-147.
13. Gyan E, Frew M, Bowen D, Beldjord C, Preudhomme C, Lacombe C, Mayeux P, Dreyfus F, Porteu F, Fontenay M (2005) Mutation in RAP1 is a rare event in myelodysplastic syndromes. Leukemia 19: 1678-1680.